#cannabisaficionado

Cannabis

CBD: The Game-Changing Cannabinoid That Shook the World

CBD, one of the most discussed and marketed elements of the cannabis plant, offers significant appeal based on its wide-ranging medicinal efficacy.

Published

on

CBD
PHOTO | Gracie Malley
Advertisement Back2Grow Advertisement

The wave of adult use cannabis legalization sweeping North America has introduced the various benefits and efficacies of this nuanced and controversial herb to tens of millions of consumers. From suburban soccer moms in Seattle to software developers in Boston to artists in Los Angeles, America is discovering the cannabis plant. Many consumers, however, either aren’t comfortable with or simply can’t tolerate the psychoactive properties of the most infamous molecule in cannabis, tetrahydrocannabinol (THC). This is where THC’s non-psychotropic chemical cousin, cannabidiol (CBD), plays a starring role.

Despite this major difference, CBD and THC have many characteristics in common, including their anti-inflammation, anti-cancer, and pain killing properties. Many products offer special ratios of THC and CBD, purported to deliver optimal effects for particular lifestyle consumers and patients.

The Details of CBD

CBD, one of the most discussed and marketed elements of the cannabis plant, offers significant appeal to consumers based on its wide-ranging medicinal efficacy and lack of overt psychoactive effect. This major cannabinoid has been shown, via clinical research studies and anecdotal evidence, to help those suffering from anxiety, chronic pain, depression, inflammation, psychosis, and seizures—as well as their associated diseases.

CBD’s promise extends beyond life-threatening conditions such as cancer to arthritis, diabetes, chronic pain, epilepsy, Parkinson’s disease, PTSD, and even schizophrenia. This special molecule features neuroprotective qualities, including anti-cancer properties.

For nearly a century, cannabis has been cultivated on the black market to enhance its THC content and potency, not for CBD. The emergence of legal markets, however, has featured much activity among cannabis breeders, cultivators, and companies wanting to provide consumers with many of the health benefits of THC, but without the “high.” Cannabis strains rich in CBD include ACDC, Charlotte’s Web, Dancehall, Dance World, Hawaiian Dream, Nordie, Remedy, Ringo’s Gift, Sour Tsunami, and Suzy Q.

The Research

A 2016 study entitled “CBD-enriched Medical Cannabis for Intractable Pediatric Epilepsy” and published in the journal Seizure found CBD to be “a promising treatment for intractable epilepsy.” The study concluded that CBD delivered only minor and infrequent side effects and provides relief for epilepsy patients who gain little or no value from traditional therapies and pharmaceutical drugs.

A 2014 study entitled “The Case for Medical Marijuana in Epilepsy” and published in the journal Epilepsia illustrated some of the nuances of bioavailability and cannabis consumption. The study pointed out the fact that “smoked and vaporized cannabis requires heat, which may alter the putative antiepileptic substance(s), whereas ingested cannabis must survive the acidic environment of the stomach and metabolism [by the liver].”

The study concluded, “Part of the challenge of understanding why cannabis has apparently contradictory effects in epilepsy likely has to do with the complexity of the plant itself. Cannabis sativa has 489 known constituents, only [113] of which are cannabinoids, with the remainder including potentially neuroactive substances such as terpenes, hydrocarbons, ketones, aldehydes, and other small hydrophobic compounds capable of crossing the blood-brain barrier.”

Cannabis

Cannabis Shoppers Expect Tax Savings to Reach the Shelf. Will They?

A NuggMD survey reported this week finds that 74 percent expect cannabis companies to pass on tax savings. The result measures consumer expectations, not an observed price cut.

Published

on

A hand using a pink calculator beside receipts and paperwork.

Cannabis consumers are looking for a share of the savings if federal tax relief improves operators’ finances. A NuggMD poll reported November 3 found that 74 percent of respondents expect companies to pass along savings through lower prices if rescheduling brings tax relief. The result captures a clear consumer expectation. It does not establish that prices have fallen or that every cannabis business receives the same relief.

Marijuana Moment’s Tom Angell reported the findings from 654 consumers in state-legal markets surveyed October 8–15. The reported margin of error was approximately 3.83 percentage points. Twenty-six percent expected companies to retain the savings while keeping prices at their current level.

What the survey can tell us

The question was conditional: it asked what consumers expected if companies received rescheduling-related tax relief. That wording is important. Respondents were not reporting a verified reduction in a particular operator’s tax bill, and they were not comparing receipts before and after a change in federal policy.

The sample also consisted of cannabis consumers in legal markets, rather than all American adults. Its findings should be described within that population. The publicly reported summary provides useful dates, sample size and question wording, but does not establish that every state, product category or type of consumer shares the same view.

For operators, the finding is a communication challenge as much as a pricing question. Customers may hear a headline about lower taxes and reasonably ask what it changes for them. A clear answer needs to separate the business’s actual eligibility, the timing of any benefit and the decisions it makes about retail prices.

Why Section 280E matters

Section 280E is the federal tax provision at the center of the discussion. In its April 23 announcement, Treasury and the IRS explained that the provision generally denies deductions and credits for businesses trafficking in Schedule I or II controlled substances in violation of federal or state law.

The agencies said the medical-marijuana rescheduling order generally removes that barrier for activities that, because of the order, no longer involve Schedule I or II substances. They also described planned guidance for businesses conducting multiple activities, including how expenses might be apportioned. That is a more qualified proposition than saying the tax restriction has disappeared for every cannabis sale.

Treasury’s statement anticipated a transition rule related to the taxable year containing the order’s effective date. The announcement describes expected guidance; it should not be treated as a substitute for checking the rules and advice applicable to a particular business. This article is about the consumer implications of the policy debate, rather than instructions for preparing a return.

Tax treatment is not a shelf-price rule

The IRS’s cannabis industry guidance continues to distinguish tax responsibilities from the legality of the underlying activity. Income remains reportable, and businesses must keep records and meet applicable payment and information-reporting requirements. Relief from a specific restriction does not remove the rest of the tax system.

There is also a basic distinction between lowering taxable income through a deduction and reducing a product’s price by the same dollar amount. A deduction affects how a business calculates its tax obligation. A retail price is what that business charges for a particular product. The two can be connected through business decisions without being mechanically identical.

The relevant question for a consumer is therefore more specific than whether a store sells cannabis. It is which activities qualify for the changed treatment, when that treatment applies and how the operator explains any resulting benefit.

That leaves several possibilities for any operator benefiting from relief: lower prices, investment in the business, improved financial resilience or some combination. The poll does not identify what companies will choose, and it would be premature to promise customers a uniform discount. Equally, an operator should not present a possible tax improvement as evidence that its shoppers have already benefited.

What consumers can actually compare

The clearest evidence for a customer is the price of a comparable purchase over time. Comparing the same product size and formulation, and distinguishing the base price from taxes or a temporary promotion, is more informative than treating a general rescheduling headline as a receipt.

Our coverage of medical cannabis registrations explains another part of the changing federal framework. Registration, tax treatment and retail pricing are related developments, but each requires its own evidence.

The survey’s immediate message is therefore straightforward: many cannabis shoppers expect a benefit they can see. Whether that expectation is met will be demonstrated by actual pricing and company disclosures, rather than by a poll result or a promised future guidance document alone.

Illustrative stock budgeting photograph; not a cannabis customer or company account. Photo: Kaboompics / Pexels.

Continue Reading

Cannabis

Houston’s Cannabis Enforcement Vote Now Turns to Implementation

Houston’s approved charter change focuses on police priorities, diversion and public accounting. It does not create a legal cannabis market or guarantee that possession cannot lead to enforcement.

Published

on

Houston voters have approved a charter amendment directing city police to give Class A and Class B misdemeanor marijuana possession their lowest enforcement priority. The cannabis provision sits alongside a ban on no-knock warrants in Proposition A, also called the Houston Freedom Act. The next part of the story is how the city translates those instructions into budgets, police policies, training and public reports.

Tom Angell’s election-night report for Marijuana Moment described the measure as approved, with an early count showing roughly 72 percent support. That was a preliminary result, rather than a certified final percentage. The policy’s meaning is best assessed against the charter language published by the city.

Lower priority has a defined scope

The text directs the Houston Police Department to make the specified misdemeanor possession offenses its lowest possible enforcement priority unless a binding state or federal court action requires otherwise. It calls for corresponding changes to the annual budget, department manual and relevant procedures. That links the policy to how the city allocates work and resources, not just to a statement of preference.

The charter language also preserves limits that matter to residents. An officer who has probable cause to believe a substance is marijuana may seize it and must explain the grounds in a report. The diversion section preserves law-enforcement and prosecutorial discretion to enforce state law. A lower-priority directive therefore should not be described as a guarantee against a police encounter, seizure or prosecution.

Nor does a city enforcement measure establish a state-licensed adult-use market. It does not create retail licenses or set up a new system for purchasing cannabis. Those are different legal questions from how municipal personnel prioritize a category of existing offenses. The practical distinction is essential for anyone reading the outcome as permission to possess or sell marijuana.

Diversion is part of the design

The measure supports diversion where legally permissible for people accused of the covered offenses. Examples in the text include mental-health or substance-use treatment referrals, community service and other alternatives to arrest or prosecution consistent with the cited Texas criminal-procedure provision.

That language describes a policy direction with legal qualifications. It does not promise that every individual will receive the same referral or qualify for the same alternative. Implementation will need to show what options are actually available and how decisions are made. An announcement that a measure passed cannot answer those case-specific questions.

The campaign organization Ground Game Texas promoted the Houston Freedom Act as an effort to redirect police resources and change marijuana enforcement. Its support explains the initiative’s advocacy context. The adopted language, subsequent city policies and actual enforcement records will be more useful for assessing results than campaign expectations alone.

The accounting provisions deserve attention

The city’s published text requires a one-time review of misdemeanor marijuana enforcement during the preceding five years. The audit is to include arrests, citations and demographic information, alongside estimates of staff hours, per-charge costs and spending on THC testing and enforcement. It is intended to be presented at a public council meeting and made available online.

The annual reporting requirement adds another way to follow implementation. The text calls for information including arrests, citations, diversion referrals, demographic breakdowns and estimated staff hours. This creates a framework for asking whether the new priority is reflected in practice. A report’s existence would not establish success on its own; the contents and their consistency over time will matter.

The THC-testing provisions similarly seek visibility into spending and staff time. That is a different question from whether testing can ever occur. The charter text contemplates council funding for testing when a compelling public-safety purpose is identified. Readers should avoid turning a budget-transparency provision into a claim that the city has prohibited every test.

What to watch after the vote

The no-knock provision is a separate substantive part of the same amendment. It bars Houston officers from requesting or executing warrants that do not require announcement and a wait of at least 15 seconds before entry. Its inclusion helps explain why Proposition A cannot be reduced to a cannabis-only retail or possession proposal.

For cannabis readers, the useful next milestones are official election certification, implementation instructions and the required public accounting. Those will show how the city applies a lower-priority policy while operating within the legal limits stated in the measure.

Our Idaho ballot coverage concerned who could change cannabis law. Houston’s vote concerns municipal enforcement priorities. Both involve voter participation, but their effects should be judged on the specific language voters approved rather than treated as interchangeable forms of legalization.

Illustrative stock view of Houston; not election-night photography. Photo: Eddie O. / Pexels.

Continue Reading

Cannabis

Massachusetts and Idaho Voters Keep Two Different Cannabis Doors Open

Election-night cannabis victories in Massachusetts and Idaho have different practical effects: one protects an existing market, while the other preserves a route to future reform.

Published

on

Boston skyline across a waterfront under a bright sky.

Cannabis voters delivered two significant results on November 3: Massachusetts rejected an effort to dismantle its adult-use sales system, while Idaho rejected a constitutional amendment that would have restricted future citizen-led legalization. Both outcomes resist a rollback, but they leave residents in very different positions. Massachusetts keeps an existing regulated market; Idaho keeps a possible route to changing its laws.

Marijuana Moment’s Tom Angell reported Massachusetts’ rejection of Question 8, citing an Associated Press count of approximately 76 percent against with an estimated 80 percent counted Wednesday morning. Those figures describe a developing count, not a certified final tally.

Massachusetts keeps its regulated system

The Secretary of the Commonwealth’s ballot guide explains what Question 8 would have done. The proposal would have repealed the laws governing regulated, taxed adult recreational marijuana sales and changed possession rules, while retaining medical cannabis. Existing adult-use businesses could have applied through an expedited route to become medical dispensaries.

The proposed effective date was January 1, 2028. Its defeat therefore prevents a future restructuring rather than reopening stores that had already been closed. The official guide describes a no vote as making no change to marijuana law. Consumers should not interpret the result as a new expansion of purchasing rights or a change to every rule governing cannabis.

The scale of the existing system helps explain the stakes. In a September 9 announcement, the Cannabis Control Commission said adult-use businesses had crossed $10 billion in cumulative gross sales on September 5. That is a total since retail operations began in 2018, rather than one year’s revenue or a measure of industry profit.

The commission also reported $1.65 billion in adult-use sales during calendar 2025. Its release described hundreds of operating businesses and roughly 15,000 individual employees in the adult-use industry. Those agency figures supply context for the market voters chose to retain; they do not, by themselves, settle every disagreement raised during the campaign.

WBUR’s Simón Rios places the decision in a longer sequence: Massachusetts decriminalized marijuana in 2008, approved medical cannabis in 2012 and voted for adult-use legalization in 2016. Those changes addressed different parts of the legal framework. The latest vote preserves the commercial system that developed afterward rather than repeating the original legalization decision. That chronology also explains why keeping adult-use sales and preserving medical access were separate questions in the repeal debate. An established medical program would not have made the proposed loss of adult-use businesses immaterial to customers who use those stores.

Idaho preserves a process, not a retail market

Idaho’s result concerns who can pursue changes in the future. The official state results dashboard, checked Wednesday morning, showed HJR 4 losing with approximately 66 percent voting no. All 44 counties were listed as reporting, and the dashboard continued to label its returns unofficial.

The amendment would have given only the Legislature authority to legalize listed activities involving marijuana, narcotics or other psychoactive substances. Its defeat does not enact a medical cannabis program, authorize adult-use stores or approve possession. It leaves the proposed restriction out of the constitution.

The Secretary of State’s explanation makes the procedural difference explicit: a no vote retains the ability for citizens to initiate statutes legalizing or decriminalizing the covered substances. That possibility is the door voters kept open. A future measure would still need to qualify and then win approval.

The same official page lists the Idaho Medical Cannabis Act among initiatives that did not qualify for the 2026 ballot. It describes signature requirements applying both statewide and across legislative districts. Defeating HJR 4 does not retroactively qualify that unsuccessful proposal or turn support for initiative rights into approval of its policy terms.

Why the distinction matters

For a Massachusetts customer, the immediate significance is continuity in the state’s adult-use framework. For an Idaho resident interested in reform, it is preservation of a political mechanism. Describing both results simply as legalization wins would blur the most important practical difference between them.

The two votes also answer narrower questions than a nationwide referendum on cannabis. Massachusetts considered a specific repeal proposal; Idaho considered a specific allocation of constitutional authority. Neither result establishes what every voter believes about particular products, medical conditions, possession limits or commercial licensing.

Our pre-election HJR 4 coverage explains the choice Idaho faced before polls closed. This outcome report follows that separate stage of the story. As election officials complete their work, readers should distinguish unofficial totals from certification and, just as carefully, a preserved reform process from a law that actually permits cannabis access.

Illustrative stock view of Boston; not election-night photography. Photo: Mohan Nannapaneni / Pexels.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.